St. Jude/Cambridge Heart sales
This article was originally published in The Gray Sheet
St. Jude Medical will market Cambridge Heart's HearTwave II microvolt t-wave alternans test to North American primary care and internal medicine physicians under an amendment to the firms' three-year marketing agreement, they announce June 18. Under the original deal, signed in March, St. Jude was only to target electrophysiologists and cardiologists for sales of the product, which is used to stratify patients by risk for implantable defibrillator need (1"The Gray Sheet" March 26, 2007, p. 8). Cambridge Heart's reps, who originally addressed the primary care and internal medicine market, will now support St. Jude's team in all physician markets...
You may also be interested in...
St. Jude Medical's endorsement of microvolt t-wave alternans testing under a co-marketing agreement with test maker Cambridge Heart will help accelerate adoption of the technology, which guides appropriate defibrillator patient selection, both companies say
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.